Literature DB >> 22386676

Cerebral malaria: what is known and what is on research.

F Gay1, S Zougbédé, N N'dilimabaka, A Rebollo, D Mazier, A Moreno.   

Abstract

Malaria is still the world's major important parasitic disease and is responsible for the death of more people than any other communicable disease except tuberculosis. A major change in recent years has been the recognition that severe malaria, predominantly caused by Plasmodium falciparum, is a complex multi-system disorder presenting with a range of clinical features. Some surviving patients have an increased risk of neurological and cognitive deficits, behavioural difficulties and epilepsy, making cerebral malaria a leading cause of childhood neurodisability in the malaria transmission area. It is unclear how an intravascular parasite causes such brain injury. Understanding of these mechanisms is important to develop appropriate neuroprotective interventions. However, due to the high specificity of P. falciparum to the human host and to the fact that clinical studies in human are not always feasible, our knowledge about this syndrome mainly comes from autopsy studies which can only give us a limited view of this deadly syndrome. Efforts developed by the scientific community have shown that development of severe malaria probably results from a combination of parasite-specific factors such as adhesion and sequestration to the vascular endothelium, the release of bioactive molecules, together with host inflammatory responses and metabolic acidosis. Recent studies have shown that endothelial cells could play a central role in the onset of the severe malaria. Indeed, adhesion of parasitized erythrocytes to these cells could drive their activation, which could participate in the trigger of an immune response and haemostatic derangements. Moreover, death of endothelial cells could be at the origin of the blood-lung/brain barrier breakdown. Despite the efforts to find new mechanisms, which explain the physiopathology of severe malaria, research progress is slowed down by the lack of experimental models, which reproduce this complex multi-system disorder. In absence of a vaccine so far, the rapid diagnosis of the disease, an efficient treatment, a correct management and nursing care are the only weapons to control mortality due to P. falciparum. It is important to note that in the future, the treatment of severe malaria may involve adjuvant treatments in addition to a potent antimalarial drug. In the present review, we summarize both what is known and practically useful for a physician, and the most promising and current topics of research.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22386676     DOI: 10.1016/j.neurol.2012.01.582

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  14 in total

1.  Assessing the performance of CareStart Malaria Pf/Pv Combo Test against thick blood film in the diagnosis of malaria in northwest Ethiopia.

Authors:  Tadesse Hailu; Tadesse Kebede
Journal:  Am J Trop Med Hyg       Date:  2014-03-31       Impact factor: 2.345

2.  APRONES: neurology research and education in the Democratic Republic of the Congo.

Authors:  M K Luabeya; J C Mwanza; K M Mukendi; D Tshala-Katumbay
Journal:  Neurology       Date:  2013-05-07       Impact factor: 9.910

3.  NADPH Oxidase: a Possible Therapeutic Target for Cognitive Impairment in Experimental Cerebral Malaria.

Authors:  Simhadri Praveen Kumar; Phanithi Prakash Babu
Journal:  Mol Neurobiol       Date:  2021-11-16       Impact factor: 5.682

4.  A new hypothesis on the manifestation of cerebral malaria: the secret is in the liver.

Authors:  Yuri Chaves Martins; Cláudio Tadeu Daniel-Ribeiro
Journal:  Med Hypotheses       Date:  2013-08-13       Impact factor: 1.538

5.  Cyclic patterns of cerebral malaria admissions in Papua New Guinea for the years 1987-1996.

Authors:  B D Dimitrov; D Valev; R Werner; P A Atanassova
Journal:  Epidemiol Infect       Date:  2013-01-23       Impact factor: 4.434

Review 6.  Vascular dysfunction as a target for adjuvant therapy in cerebral malaria.

Authors:  Leonardo José de Moura Carvalho; Aline da Silva Moreira; Cláudio Tadeu Daniel-Ribeiro; Yuri Chaves Martins
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-08       Impact factor: 2.743

Review 7.  Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives.

Authors:  Remington L Nevin; Ashley M Croft
Journal:  Malar J       Date:  2016-06-22       Impact factor: 2.979

8.  Cerebral malaria: insight into pathogenesis, complications and molecular biomarkers.

Authors:  Farah Hafiz Yusuf; Muhammad Yusuf Hafiz; Maria Shoaib; Syed Ahsanuddin Ahmed
Journal:  Infect Drug Resist       Date:  2017-02-02       Impact factor: 4.003

9.  Comparison of apoptosis in human primary pulmonary endothelial cells and a brain microvascular endothelial cell line co-cultured with Plasmodium falciparum field isolates.

Authors:  Jean Claude Biteghe Bi Essone; Nadine N'Dilimabaka; Julien Ondzaga; Jean Bernard Lekana-Douki; Dieudonné Nkoghe Mba; Philippe Deloron; Dominique Mazier; Frédrérick Gay; Fousseyni S Touré Ndouo
Journal:  BMC Infect Dis       Date:  2017-06-27       Impact factor: 3.090

10.  Pharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malaria.

Authors:  Nana O Wilson; Wesley Solomon; Leonard Anderson; John Patrickson; Sidney Pitts; Vincent Bond; Mingli Liu; Jonathan K Stiles
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.